Trevi Therapeutics to Share Financial Results and Updates
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a biopharmaceutical company focused on developing innovative therapies, has scheduled a conference call and an audio webcast. This session will allow the company to present its first quarter 2025 financial results as well as important corporate updates.
Details of the Upcoming Conference Call
The conference call is set for Thursday evening at 4:30 p.m. ET. Participants can join by dialing the domestic number (877) 870 4263, with an alternative international option at (412) 317 0790. No access code will be needed for those joining the call.
How to Access the Webcast
Investors and interested parties can also access the live audio webcast from the 'Investors & News' section of Trevi Therapeutics’ official website. An archived version of the conference call will be available for replay for a period of 30 days following the event.
About Trevi Therapeutics and Its Innovative Approach
Trevi Therapeutics is making strides in the development of Haduvio™, an investigational therapy designed for the treatment of chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). This product represents a significant advancement in addressing chronic cough, a prevalent and debilitating condition for many patients.
The Impact of Chronic Cough on Patients
Chronic cough is not only a frequent symptom found in IPF patients but also a troubling condition affecting many lives. Around 85% of individuals with IPF experience chronic cough, leading to potential complications such as disease progression and reduced quality of life. Furthermore, patients may find themselves coughing excessively — up to 1,500 times a day — which can adversely impact social interactions and daily activities.
Overview of Haduvio™ and Its Mechanism of Action
Haduvio™ is designed to modulate the cough reflex through innovative pathways. As a kappa agonist and a mu antagonist, it acts on the brain and peripheral systems, targeting opioid receptors that are crucial in managing cough. Notably, nalbuphine, its active ingredient, is not classified as a controlled substance by the U.S. Drug Enforcement Agency.
Understanding Refractory Chronic Cough
Refractory chronic cough is characterized by a cough lasting over eight weeks, despite patients receiving treatment for underlying conditions like asthma or gastroesophageal reflux disease. It affects 2 to 3 million individuals in the U.S., presenting substantial challenges not just for patients but also for their families and caregivers.
Future Outlook for Trevi Therapeutics
As the FDA and other regulatory bodies continue to evaluate therapies for chronic cough, Trevi remains committed to its mission of developing effective treatments for patients. Their ongoing trials and the promising results from Haduvio™ could pave the way for approval and availability of new treatment options for those suffering from chronic cough.
Frequently Asked Questions
What is the focus of Trevi Therapeutics?
Trevi Therapeutics is focused on developing innovative therapies, particularly for chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.
When will Trevi report its financial results?
The financial results for the first quarter of 2025 will be shared on May 8, 2025, during a conference call at 4:30 p.m. ET.
How can I participate in the Trevi conference call?
You can join the conference call by calling the provided numbers or by accessing the webcast on Trevi Therapeutics’ website.
What is Haduvio™?
Haduvio™ is an investigational therapy aimed at reducing cough frequency, developed specifically for chronic cough in IPF and RCC patients.
What are the statistics about chronic cough in IPF patients?
Chronic cough impacts around 85% of the IPF population, causing significant disruptions in their lives and health.
